Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2007.

Publication: PR Newswire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2007 PR Newswire Association LLC

-- Data from Phase III pivotal trial demonstrate safety and efficacy of first FDA-approved nebulized formoterol fumarate for patients with moderate to severe COPD --

NAPA, Calif., May 16 /PRNewswire/ -- Dey, L.P. announced that two clinical data presentations will be given at the International Conference of the American Thoracic Society (ATS) on Sunday, May 20, at the Moscone Center in San Francisco. The presentations will detail Phase III clinical data demonstrating the safety and efficacy of Perforomist(TM) (formoterol fumarate) Inhalation Solution, approved on May 11 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

For those attending ATS, the two presentations are available as follows: -- "Nebulized Formoterol is an Effective Bronchodilator and Improves the Quality of Life for...

Read the full article for free courtesy of your local library.